Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab
Indication
Treating COVID-19 (NICE TA878)
NICE TA878 - Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19
Red
Brand:
Nice TA:
878
Commissioning responsibility:
PbR excluded:
No
BNF chapter:
Infection
Background
1.1 Nirmatrelvir plus ritonavir is recommended as an option for treating COVID‑19 in adults, only if they:
- do not need supplemental oxygen for COVID‑19 and
- they have any of the following:
- an increased risk for progression to severe COVID‑19, as defined in section 5
- age 70 years and over
- a body mass index (BMI) of 35 kg/m2 or more
- diabetes
- heart failure.